SCHEMBL1506150

SCHEMBL1506150

COC(=O)Cc1cc(Nc2cc(Cl)cc(OC)c2)nn1-c1ccnc(C)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 1/20 0.37
▸ EGFR P00533 2/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ MAPK1 P28482 7/20 0.35
▸ P2RX3 P56373 2/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ WNT3A P56704 1/20 0.33
▸ CCNE1 P24864 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ ERBB3 P21860 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ RAB9A P51151 1/20 0.32
▸ PHGDH O43175 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506184 0.91 P2RX7 (0.38) P2RX7EGFRFGFR1MAPK1P2RX3
SCHEMBL1506337 0.89 P2RX7 (0.41) P2RX7EGFRFGFR1MAPK1WNT3A
SCHEMBL1506232 0.88 EGFR (0.35) P2RX7EGFRFGFR1MAPK1ERBB3
SCHEMBL1506194 0.88 RXRA (0.41) P2RX7EGFRFGFR1MAPK1P2RX3
SCHEMBL10009231 0.88 CCNE1 (0.39) P2RX7MAPK1CCNE1CDK2
SCHEMBL1506201 0.86 HDAC3 (0.42) MAPK1MEN1MAPTKMT2ACDK2
SCHEMBL10009346 0.86 CCNE1 (0.38) MAPK1MEN1KMT2ASMN1; SMN2CCNE1
SCHEMBL1506191 0.86 EGFR (0.34) P2RX7EGFRFGFR1MAPK1P2RX3
SCHEMBL10008929 0.85 ALOX5 (0.36) P2RX7EGFRFGFR1MAPK1P2RX3
SCHEMBL10008600 0.85 F10 (0.39) P2RX7MAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791144-B2 Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV (BE) 2014-07-29 — — US disclosed
EP-2491024-B1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2013-11-20 — — EP disclosed
EP-2491024-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES Janssen Pharmaceutica N.V. (BE) 2012-08-29 — — EP disclosed
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines JANSSEN PHARMACEUTICA NV (BE) 2012-07-05 — — US disclosed
WO-2011033018-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines CHRM1, CHRNA1, CHRM3 P2RX7 43/4885EGFR 966/4885FGFR1 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback